// App-Quantinova.ai

: Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) in Transplant-Ineligible Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM): Clinical Assessment of Key Subgroups of the Phase 3 Maia Study

Researchers

Presenter

  • Philippe Moreau

Principal Investigators

  • Saad Usmani

  • Nizar Jacques Bahlis

  • Noopur Raje

  • Torben Plesner

  • Robert Z. Orlowski

  • Supratik Basu

  • Hareth Nahi

  • Cyrille Hulin

  • Hang Quach

  • Hartmut Goldschmidt

  • Michael O'Dwyer

  • Aurore Perrot

  • Christopher P. Venner

  • Katja Weisel

  • Mourad Tiab

  • Margaret Macro

  • Laurent Frenzel

  • Xavier Leleu

  • Huiling Pei

  • Maria Krevvata

  • Robin Carson

  • Fredrik Borgsten

  • Shaji K Kumar

Medical Centers

  • CHD Vendée, La Roche sur Yon, France

  • BC Cancer - Vancouver Centre Group, Vancouver, Canada

  • Department of Medical Oncology, Cross Cancer Institute, University of Alberta, Edmonton, Canada

  • Karolinska Institute, Department of Medicine, Division of Hematology, Karolinska University Hospital at Huddinge, Stockholm, Sweden

  • University of Melbourne, St. Vincent's Hospital, Melbourne, Australia

  • CHU Poitiers, Hôpital la Milétrie, Poitiers, France

  • Vejle Hospital and University of Southern Denmark, Vejle, Denmark

  • Memorial Sloan Kettering Cancer Center, New York, NY

  • Centre Hospitalier Universitaire (CHU) de Caen, Caen, France

  • Hopital Necker-Enfants Malades, Paris, France

  • Hematology Department, University Hospital Hôtel-Dieu, Nantes, France

  • Royal Wolverhampton NHS Trust and University of Wolverhampton, CRN West Midlands, NIHR, Wolverhampton, United Kingdom

  • Department of Lymphoma and Myeloma, MD ANDERSON CANCER CENTER, HOUSTON, TX

  • Center for Multiple Myeloma, Massachusetts General Hospital, Boston, MA

  • Department of Medicine/Haematology, NUI, Galway, Ireland

  • University Hospital Heidelberg, Internal Medicine V and National Center for Tumor Diseases (NCT), Heidelberg, Germany

  • Arnie Charbonneau Cancer Research Institute, University of Calgary, Calgary, Canada

  • Department of Oncology, Hematology and Bone Marrow Transplantation with Section of Pneumology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany

  • Department of Hematology, Hôpital Haut Lévêque, University Hospital, Pessac, France

  • University of Lille, CHU Lille, Service des Maladies du Sang, Lille, France

  • CHU de Toulouse, IUCT-O, Université de Toulouse, UPS, Service d'Hématologie, Toulouse, France

  • Department of Hematology, Mayo Clinic Rochester, Rochester, MN

Locations

  • France

  • United States

  • Canada

  • United Kingdom

  • Denmark

  • Germany

  • Sweden

  • Ireland

  • Australia

Companies

  • JB Medical Ltd.

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Multiple Myeloma

Biomarkers

  • N/A

Drug/Treatment

  • Dexamethasone

  • Dekpak 13 Day Taperpak

  • Lenalidomide

  • daratumumab Intravenous

Outcome

  • N/A

Study Design

  • Randomized

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved